Holen Sie sich die Stockscreener-App
0.8633
8.65%
-0.0817
Handel nachbörslich:
.86
-0.0033
-0.38%
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
IO Biotech (IOBT) to Release Quarterly Earnings on Tuesday - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire
Artivion (AORT) Q4 Earnings: What To Expect - The Globe and Mail
Should You Buy IonQ Stock Before Feb. 26? - The Globe and Mail
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - The Manila Times
IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference - Nasdaq
Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach - StockTitan
32,667 Shares in IO Biotech, Inc. (NASDAQ:IOBT) Purchased by Vontobel Holding Ltd. - Defense World
IO Biotech to Present at the 45th Annual Cowen Health Care Conference - The Manila Times
IO-112 modulates tumor macrophages, allows control of tumor microenvironment - BioWorld Online
IO Biotech (NASDAQ:IOBT) Trading Up 4.2%Here's What Happened - MarketBeat
Head and Neck Squamous Cell Carcinoma Market Analysis 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, NDA Approval, Epidemiology and Companies by DelveInsight - Barchart
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in the 7MM Amid Immunotherapy Advancements, Predicts DelveInsight - Yahoo Finance
3 Tech Defense Stocks That Could Be the Next Palantir - The Globe and Mail
Prediction: ASML Will Beat the Market. Here's Why. - The Globe and Mail
Multiomics and AI in Healthcare: A New Frontier for Drug Discovery - Securities.io
Clinical Trials News Live Feed - StockTitan
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review | Evaxion Biotech, Nouscom, Amgen, Dendreon Pharma, IO Biotech - Barchart
Neoantigen Based Personalized Cancer Therapeutic Vaccines - openPR
Full Stock Market News from 2025-02-07 - StockTitan
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate - Marketscreener.com
Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR
IO Biotech advances cancer vaccine candidate IO112 - MSN
IO Biotech advances cancer vaccine candidate IO112 By Investing.com - Investing.com Canada
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate - The Manila Times
Hill International Providing Program Management and Oversight Services to Support the Port of Oakland's Capital Improvement Program - The Manila Times
IO Biotech Publishes Preclinical Results for IO112 Cancer Vaccine, IND Submission Expected in 2025 - Nasdaq
Revolutionary Cancer Vaccine IO112 Transforms Tumor Environment, New Study Reveals Major Breakthrough - StockTitan
Melanoma Clinical and Non-Clinical Studies, Key Companies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 68.6% in January - MarketBeat
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - Yahoo Finance
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - Morningstar
Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - Yahoo Finance
Small-Cap Miner Rallies On Exclusive Offtake Agreement - The Globe and Mail
Melanoma FDA Approvals, Pipeline Insights, Clinical Trials Assessment and Companies | DelveInsight - openPR
Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Is C3.ai Stock a Buy, Sell, or Hold on Big New McKinsey Partnership? - The Globe and Mail
GenomesDAO Secures New Investment Round From Pantera Capital and Modular Capital - ACCESS Newswire
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - MSN
Loblaw Companies Limited (L:CA) Stock Forecast: Key Takeaways for Investors in 2025 - The Globe and Mail
Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor - Healio
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40) - Marketscreener.com
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - The Manila Times
3.13%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):